Sign in Create account
Sign in and upgrade to a paid plan to export futures history as CSV.
Sign in and upgrade to a paid plan to export financials as CSV.

Lyka Labs Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: LYKALABS BSE: 500259
₹83.21
▲ 0.75 (0.91%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
31/100
Weak
Valuation
54/100
Fairly Valued
Momentum
53/100
Neutral

QVM read Mixed signals Quality Weak, Valuation Fairly Valued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹301 Cr
PE (TTM)
Data unavailable.
Price to Book
3.3
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
0.83%
FII + DII, latest filed period
Piotroski Score
5
Relative return vs Nifty50, qtr %
14.3
Relative return vs Sector, qtr %
11.2
Free Cash Flow
₹-6 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
163.64%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
0.00%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
0.20%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-53.49%
as of June 30, 2025
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
45.01%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.17
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.53
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
-8.31
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
2.79%
as of June 30, 2025
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
7.10%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
-21.60%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
-5.98%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
-7.14%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
-11.49%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

1 of 7 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 5)
  • No Debt to equity is below 0.5 (0.53)
  • No Return on equity is 15% or more (-11.5%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

2 of 3 met
  • No FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

1 of 3 met
  • No 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

1 of 5 met
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • No Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
0.9%
Low 83.2100 · High 84.1000
1W return
-4.5%
Low 82.4600 · High 88.0000
1M return
10.4%
Low 73.0000 · High 88.0000
52W return
-14.4%
Low 44.1000 · High 100.9400
Lifetime High ₹254.3000 (Dec. 23, 2021)
Lifetime Low ₹8.7000 (March 25, 2013)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish4
Bearish2
5D
84.0
10D
83.9
20D
81.9
50D
76.6
100D
72.7
200D
68.0

Delivery and volume

Day avg. delivery
100.0%
Week avg. delivery
100.0%
Month avg. delivery
100.0%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

83.51
Pivot
First resistance83.80
Second resistance84.40
Third resistance84.69
First support82.91
Second support82.62
Third support82.02
Day RSI58.2
Day MFI90.0
Day MACD2.91
Day MACD signal3.39

Beta

1M0.61
3M0.72
1Y1.10
3Y1.03

Price change analysis

↑ 10.4%
Over 1 Month
LowHigh
73.0088.00
↑ 11.2%
Over 3 Months
LowHigh
58.0088.00
↑ 62.6%
Over 6 Months
LowHigh
49.3388.00
↓ -14.4%
Over 1 Year
LowHigh
44.10100.94
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →

Data unavailable (needs at least 2 historical quarters with both a filed EPS and a matching trading day).

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹42 Cr
Net profit (June 30, 2026)
₹2 Cr
Basic EPS (June 30, 2026)
₹0.5800

Ranks #109 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter58.45%
  • Mutual funds0.01%
  • FII/FPI0.17%
  • Other DII0.65%
  • Public40.72%

Largest holders

NameCategoryShares %Shares
IPCA LABORATORIES LIMITEDPromoter40.4500%14624923
KUNAL NARENDRA GANDHIPromoter10.0300%3625000
NEHAL NARENDRA GANDHIPromoter3.6000%1300000
ENAI TRADING AND INVESTMENT PVT. LTDPromoter3.0400%1100000
THERMO CAPITAL PRIVATE LIMITEDPublic1.9400%701618

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings increased from 58.16% to 58.45% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings decreased from 0.29% to 0.17% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings were unchanged at 0.01% in Jun 2026 qtr

All shareholding details →

Insider trading, SAST & pledges

All 30 insider trades, 27 SAST, 79 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
17 Apr 2024 Ipca Laboratories Limited Promoter Buy 0 ₹0
12 Jul 2023 Nehal N. Gandhi Promoter Buy 0 ₹0
12 Jul 2023 Nehal N. Gandhi Promoter Buy 0 ₹0
12 Jul 2023 Nehal N. Gandhi Promoter Buy 0 ₹0
12 Jul 2023 Nehal N. Gandhi Promoter Buy 0 ₹0
28 Jun 2023 Narendra I Gandhi HUF Promoter Sell 0 ₹0
28 Jun 2023 Kunal Gandhi Promoter Buy 0 ₹0
20 Apr 2023 Ipca Laboratories Limited Promoter Buy 0 ₹0
3 Apr 2023 Nehal N. Gandhi Promoter Buy 0 ₹0
3 Apr 2023 Narendra I Gandhi Promoter Sell 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 277 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
2 Jun 2023 QUANT MUTUAL FUND QUANT SMALL CAP FUND Bulk Sell 150,000 101.9300 NSE
26 May 2023 PRABHULAL LALLUBHAI PAREKH Bulk Buy 185,061 91.9700 NSE
26 May 2023 PRABHULAL LALLUBHAI PAREKH Bulk Sell 168,148 92.6100 NSE
25 Aug 2022 XTX MARKETS LLP Bulk Buy 149,216 148.2500 NSE
25 Aug 2022 XTX MARKETS LLP Bulk Sell 145,633 148.9300 NSE
24 Aug 2022 VEENA RAJESH SHAH Bulk Sell 200,542 136.4100 NSE
24 Aug 2022 VEENA RAJESH SHAH Bulk Buy 200,542 134.5100 NSE
24 Aug 2022 SUVARNA KUMARI AGRAWAL Bulk Sell 270,000 138.3100 NSE
24 Aug 2022 RIKEEN P DALAL HUF Bulk Buy 380,626 138.2500 NSE
24 Aug 2022 CESTRUM CORPORATE ADVISORS LLP Bulk Buy 300,000 138.2700 NSE

All bulk and block deals →

Corporate Actions

Full history (19 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
1 Aug 2024OTHERAnnual General Meeting
21 Jul 2023OTHERAnnual General Meeting
21 Jul 2022OTHERAnnual General Meeting
22 Jul 2021OTHER Annual General Meeting
16 Sep 2020OTHER Annual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
10 Aug 2026 Financial Results Yes
25 May 2026 Financial Results Yes
31 Mar 2026 Other business matters —
29 Jan 2026 Financial Results Yes
12 Nov 2025 Financial Results/Other business matters Yes

Corporate Announcements

All 628 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
24 Sep 2026 Trading Window Lyka Labs Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
12 Aug 2026 Copy of Newspaper Publication Lyka Labs Limited has informed the Exchange about Copy of Newspaper Publication
11 Aug 2026 Shareholders meeting Lyka Labs Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 10, 2026. Further, the company has informed the Exchange regarding voting results.
11 Aug 2026 General Updates Lyka Labs Limited has informed the Exchange about General Updates
10 Aug 2026 Shareholders meeting Lyka Labs Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 10, 2026
10 Aug 2026 General Updates Lyka Labs Limited has informed the Exchange about General Updates
10 Aug 2026 Outcome of Board Meeting Lyka Labs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
20 Jul 2026 Copy of Newspaper Publication Lyka Labs Limited has informed the Exchange about Copy of Newspaper Publication
17 Jul 2026 General Updates Lyka Labs Limited has informed the Exchange about General Updates
17 Jul 2026 General Updates Lyka Labs Limited has informed the Exchange about General Updates

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Strong revenue growth YoY (45.0%)

Weaknesses

  • Low Return on Equity (-11.5%)
  • Thin net profit margin (2.8%)
  • Declining profit YoY (-53.5%)

Opportunities

Data unavailable.

Threats

  • Weak interest coverage (-8.3x) -- limited cushion against rising rates

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Lyka Labs Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.